Fluor
Corporation (NYSE: FLR) has been awarded an engineering,
procurement, construction and construction management contract by Novo
Nordisk for its new $2 billion diabetes Active Pharmaceutical Ingredient
(API) manufacturing facility in Clayton, North Carolina. Fluor has been
providing basic design services since Novo Nordisk announced plans for
the new facility in August 2015 and now will be executing the full scope
of work. Fluor booked its $1.2 billion value of the investment in the
fourth quarter of 2016.
“Fluor is honored to have the opportunity to assist Novo Nordisk in
building this world-class facility in North Carolina to provide modern
treatments to diabetes patients,” said Juan
G. Hernández, president of Fluor’s Life Sciences and Advanced
Manufacturing business. “This project is the single largest life
sciences facility investment in North Carolina’s history, which fits
well with Fluor’s legacy of building numerous significant life sciences
and manufacturing projects in the southeast United States.”
“Novo Nordisk selected Fluor for this critical project, the largest in
our history, based on their strong safety culture, technical competence
in the life sciences industry and ability to deliver the full scope of
work,” said Morten Nielsen, senior vice president, Novo Nordisk, and
responsible for the construction of the new facility. “We look forward
to continued strong cooperation for the success of this project.”
The new facility will measure more than 830,000 square feet, the
equivalent of nearly seven football fields, and will produce life-saving
medicines for use by patients around the world.
Nearly 2,500 craft employees and subcontractor jobs are expected at peak
construction with about 700 new jobs at the facility when it is
completed. Fluor participated in a groundbreaking event this past
spring, and its Greenville, South Carolina office is leading the
project, leveraging Fluor’s global resources as needed. Construction is
expected to be completed in mid-2019.
Fluor’s unique integrated solutions model will enable the company to
leverage its global expertise across business lines such as power
generation, as well as its staffing and construction equipment entities,
water expertise and others for this project.
About Fluor Corporation
Fluor
Corporation (NYSE: FLR) is a global engineering, procurement,
fabrication, construction and maintenance company that designs, builds
and maintains capital-efficient facilities for its clients on six
continents. For more than a century, Fluor has served our clients by
delivering innovative and integrated solutions across the globe. With
headquarters in Irving, Texas, Fluor ranks 155 on the FORTUNE 500
list with revenue of $18.1 billion in 2015 and has more than 60,000
employees worldwide. For more information, please visit www.fluor.com
or follow us on Twitter @FluorCorp.
About Novo Nordisk
Novo Nordisk
is a global healthcare company with more than 90 years of innovation and
leadership in diabetes care. Headquartered in Denmark, Novo Nordisk
employs approximately 42,000 people in 75 countries and markets its
products in more than 180 countries. For more information, visit novonordisk.com.
Fluor CorporationMedia Relations:Brian Mershon, 469-398-7621Brett Turner, 864-281-6976orInvestor Relations:Geoff Telfer, 469-398-7070Jason Landkamer, 469-398-7222